Yoonhui Choe, PMHNP | |
14255 Sw Brigadoon Ct, Beaverton, OR 97005-3369 | |
(503) 541-1475 | |
(503) 641-8548 |
Full Name | Yoonhui Choe |
---|---|
Gender | Female |
Speciality | Nurse Practitioner - Psychiatric/mental Health |
Location | 14255 Sw Brigadoon Ct, Beaverton, Oregon |
Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
Identifier | Type | State | Issuer |
---|---|---|---|
1306947726 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
363LP0808X | Nurse Practitioner - Psychiatric/mental Health | (Oregon) | Primary |
Entity Name | Western Psychological And Counseling Services Pc |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1912008178 PECOS PAC ID: 7719975085 Enrollment ID: O20040505000049 |
News Archive
While radiation treatments deliver precise doses of high-energy X-rays to stop cancer cells from spreading or to shrink tumors, oncologists have become increasingly concerned about inadvertent exposures during head and neck cancer treatments to nerves responsible for upper body mobility.
GE Healthcare today announced that it has filed a supplemental new drug application (sNDA) that will allow the company to manufacture Optison (Perflutren Protein-Type A Microspheres Injectable Suspension, USP), within its own facility.
The Hain Celestial Group, a leading organic and natural products company providing consumers with A Healthier Way of Life™ and a leader in personal care products, is proud to announce that several sunscreens from its portfolio of brands have been named to the Environmental Working Group (EWG) "Best Beach & Sport Sunscreens" list.
Teva Pharmaceutical Industries Ltd. announced today that the U.S. Food and Drug Administration (FDA) has granted tentative approval for the Company's Abbreviated New Drug Application (ANDA) to market its generic version of Novartis' breast cancer treatment Femara® (letrozole) Tablets, 2.5 mg. Final approval of Teva's Letrozole Tablets is expected upon expiry of patent protection for the brand product in June 2011.
Children who are overweight or obese are over two and a half times more likely to suffer injuries to their upper and lower extremities following a motor vehicle crash compared with normal weight children, according to a new report from the Johns Hopkins Bloomberg School of Public Health's Center for Injury Research and Policy.
› Verified 8 days ago
Entity Name | Sokyahealth Medical Group Pc |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1447842232 PECOS PAC ID: 9739575648 Enrollment ID: O20220401000312 |
News Archive
While radiation treatments deliver precise doses of high-energy X-rays to stop cancer cells from spreading or to shrink tumors, oncologists have become increasingly concerned about inadvertent exposures during head and neck cancer treatments to nerves responsible for upper body mobility.
GE Healthcare today announced that it has filed a supplemental new drug application (sNDA) that will allow the company to manufacture Optison (Perflutren Protein-Type A Microspheres Injectable Suspension, USP), within its own facility.
The Hain Celestial Group, a leading organic and natural products company providing consumers with A Healthier Way of Life™ and a leader in personal care products, is proud to announce that several sunscreens from its portfolio of brands have been named to the Environmental Working Group (EWG) "Best Beach & Sport Sunscreens" list.
Teva Pharmaceutical Industries Ltd. announced today that the U.S. Food and Drug Administration (FDA) has granted tentative approval for the Company's Abbreviated New Drug Application (ANDA) to market its generic version of Novartis' breast cancer treatment Femara® (letrozole) Tablets, 2.5 mg. Final approval of Teva's Letrozole Tablets is expected upon expiry of patent protection for the brand product in June 2011.
Children who are overweight or obese are over two and a half times more likely to suffer injuries to their upper and lower extremities following a motor vehicle crash compared with normal weight children, according to a new report from the Johns Hopkins Bloomberg School of Public Health's Center for Injury Research and Policy.
› Verified 8 days ago
Mailing Address | Practice Location Address |
---|---|
Yoonhui Choe, PMHNP 14255 Sw Brigadoon Ct, Beaverton, OR 97005-3369 Ph: (503) 541-1475 | Yoonhui Choe, PMHNP 14255 Sw Brigadoon Ct, Beaverton, OR 97005-3369 Ph: (503) 541-1475 |
News Archive
While radiation treatments deliver precise doses of high-energy X-rays to stop cancer cells from spreading or to shrink tumors, oncologists have become increasingly concerned about inadvertent exposures during head and neck cancer treatments to nerves responsible for upper body mobility.
GE Healthcare today announced that it has filed a supplemental new drug application (sNDA) that will allow the company to manufacture Optison (Perflutren Protein-Type A Microspheres Injectable Suspension, USP), within its own facility.
The Hain Celestial Group, a leading organic and natural products company providing consumers with A Healthier Way of Life™ and a leader in personal care products, is proud to announce that several sunscreens from its portfolio of brands have been named to the Environmental Working Group (EWG) "Best Beach & Sport Sunscreens" list.
Teva Pharmaceutical Industries Ltd. announced today that the U.S. Food and Drug Administration (FDA) has granted tentative approval for the Company's Abbreviated New Drug Application (ANDA) to market its generic version of Novartis' breast cancer treatment Femara® (letrozole) Tablets, 2.5 mg. Final approval of Teva's Letrozole Tablets is expected upon expiry of patent protection for the brand product in June 2011.
Children who are overweight or obese are over two and a half times more likely to suffer injuries to their upper and lower extremities following a motor vehicle crash compared with normal weight children, according to a new report from the Johns Hopkins Bloomberg School of Public Health's Center for Injury Research and Policy.
› Verified 8 days ago
Amanda Hunt, NP Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 4145 Sw Watson Ave Ste 350, Beaverton, OR 97005 Phone: 866-849-0692 | |
Mrs. Sherry Diane Davidson, PMHNP Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 10700 Sw Beaverton-hillsdale Hwy, Park Plaza West Bld 3 Suite 547, Beaverton, OR 97005 Phone: 503-643-0428 | |
Dr. Kathleen Anne Roberts, DNP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 2725 Sw Cedar Hills Blvd Ste 200, Beaverton, OR 97005 Phone: 503-352-6000 Fax: 503-352-6081 | |
Sherry L Sweeney, CPNP Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 15455 Nw Greenbrier Pkwy, Suite 111, Beaverton, OR 97006 Phone: 503-531-2323 | |
Ms. Hillary L Corson, APRN, PMHNP-BC Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 6600 Sw 105th Ave Ste 120, Beaverton, OR 97008 Phone: 971-245-1332 Fax: 503-641-5179 | |
Ms. Victoria Lynn Keyton, NP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 4510 Sw Hall Blvd, Beaverton, OR 97005 Phone: 503-644-1171 Fax: 503-643-7443 | |
Margie Nielsen, DNP, FNP-BC Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 15950 Sw Millikan Way, Beaverton, OR 97003 Phone: 503-646-0161 Fax: 503-643-7459 |